SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly ...

GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...